WE ARE ON A MISSION
TO UNLOCK THE POWER OF CELLULAR SIGNALING TO TACKLE THE WORLD'S TOUGHEST HEALTH CHALLENGES
Nanodose Therapeutics is a global leader in developing recombinant proteins. We believe that the answer to solving chronic conditions is not "never" but rather "not yet".
We are united in a shared vision to defeat chronic health conditions that frustrate clinicians, debilitate patients, sadden caregivers and cost society. We are champions in the pursuit of scientific excellence and the importance of the scientific method. We are bold and challenge each other so that we can restore hope to the community we serve.
OUR VISION
WE ENVISION A WORLD WHERE ONE DAY OUR PATIENTS CAN EXPECT MORE FROM LIFE BECAUSE OF OUR VALUABLE TREATMENTS.
What Drives Us...
-
The thought that one day our treatments will help even just one patient
-
That all chronic conditions are possible to be treated, we just haven’t discovered yet how to do that
-
By focusing on the patient, we will always do what’s right
-
The belief that the power of nanodosing and cellular signaling can bring the efficacy AND the safety to help patients
OUR VALUES
We believe the secret sauce for creating patient solutions comes from the culture that we create inside our organization. Through the values that we hold as our foundation, we are building a patient-centered culture. At the heart of Nanodose Therapeutics is an unwavering belief that we can and need to make an impact in patients’ lives. It’s what motivates every day, and it shows in our actions.
We are not content with the status
quo. We take pride in dreaming about and looking for the next innovation that can help and equip patients to tackle the hardest conditions. It is our boldness and disregard for the problems of the present that motivates us to want and achieve more. This allows us to bring new and better products to patients – faster.
We look
for what's possible
In developing and
delivering effective medications that address chronic conditions, we priortize and focus on practical outcomes and patient well-being. We embrace cutting-edge research and technology to accelerate progress and ensure that every initiative moves towards tangible, impactful outcomes.
We are focused on results
By focusing on the power
of many versus the power of one,
we can leverage the unique strengths and talents of others to find solutions for tough healthcare and development challenges. We welcome disagreement, diverse thought, and conflict as these are the building blocks for growth and the best possible output. We’re not just content having a team – we value the high-performing team.
We ensure safety and integrity
OUR STRATEGY
We are focused on developing our lead candidate, NanoSLO, for the treatment of chronic traumatic brain injury (cTBI). We believe NanoSLO will be the first pharmaceutical product to treat the millions of people suffering from this debilitating disease. We will pursue additional indications to help patients suffering from Alzheimer's Disease, strokes, and other challenging neurodegenerative diseases. We possess the worldwide rights for the development of NanoSLO as the first step in that mission.
STRATEGIC IMPERATIVES
TAKE NANOSLO INTO THE CLINIC
A major goal for NanoSLO is to ensure that the product is in the clinic in 2026. In Australia we expect to launch a six-month Phase I Safety Trial in patients with chronic TBI that may provide evidence of safety and indications of efficacy prior to launching a Phase II efficacy trial in the US, Australia and other key markets.
DEVELOP ADDITIONAL FORMULATIONS FOR NANOSLO
We are developing other formulations of NanoSLO to allow for better product performance and different patient applications such as dementia, Alzheimer's Disease as well as applications outside neurology..
SEEK STRATEGIC PARTNERSHIPS
We look for strategic partnerships with biopharmaceutical companies, academic institutions, and non-profit organizations to develop and commercialize NanoSLO. These partnerships could provide significant funding to advance the development of NanoSLO and allow us to benefit from the expertise of our partners.
PREPARE MCC FOR THE CLINIC FOR HEDS
With adequate funding, we want to finalize our pre-clinical work on MCC and file an IND in early 2027 to begin clinical testing for the treatment of Hypermobile Ehlers-Danlos syndrome to help patients to reduce the painful and debilitating dislocations of joints.